Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Wave Life Sciences (WVE) EBITDA Margin (2016 - 2026)

Wave Life Sciences (WVE) has disclosed EBITDA Margin for 12 consecutive years, with 68.22% as the latest value for Q1 2026.

  • For Q1 2026, EBITDA Margin rose 44208.0% year-over-year to 68.22%; the TTM value through Mar 2026 reached 391.17%, down 34198.0%, while the annual FY2025 figure was 478.31%, 38861.0% down from the prior year.
  • EBITDA Margin hit 68.22% in Q1 2026 for Wave Life Sciences, up from 579.68% in the prior quarter.
  • Across five years, EBITDA Margin topped out at 14.67% in Q3 2023 and bottomed at 13712.28% in Q3 2022.
  • Average EBITDA Margin over 5 years is 2060.81%, with a median of 189.86% recorded in 2024.
  • Year-over-year, EBITDA Margin plummeted -1369515bps in 2022 and then surged 1372695bps in 2023.
  • Wave Life Sciences' EBITDA Margin stood at 53.71% in 2022, then soared by 76bps to 12.63% in 2023, then skyrocketed by 216bps to 14.61% in 2024, then crashed by -4067bps to 579.68% in 2025, then surged by 88bps to 68.22% in 2026.
  • According to Business Quant data, EBITDA Margin over the past three periods came in at 68.22%, 579.68%, and 510.3% for Q1 2026, Q2 2025, and Q1 2025 respectively.